Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors

NCT07020117 is registered in ClinicalTrials.gov with Aktis Oncology, Inc. as lead sponsor.

NCT NCT07020117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07020117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Aktis Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 22, 2025
Completion date
June 30, 2032
Enrollment
150 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, colorectal adenocarcinoma, head and neck cancer, hormone receptor positive breast adenocarcinoma, non small cell lung cancer, triple negative breast cancer (tnbc), urothelial carcinoma bladder